Contralateral Breast Cancer Risk in DCIS vs. Invasive Cancer Patients, 1989-2017

28,003 patients with ductal carcinoma in situ and 275,836 patients with stage I-III invasive breast cancer were identified from the Netherlands Cancer Registry between 1989 and 2017. This data record supports a study comparing the risk of developing contralateral breast cancer between these patient groups, accounting for factors like age and treatment. The underlying data for figures is available via figshare, while the full dataset is accessible upon request from the registry.

Use Cases

• Modeling contralateral breast cancer risk based on patient diagnosis type (DCIS vs. invasive).
• Assessing the impact of (neo)adjuvant systemic therapy on secondary cancer incidence.
• Evaluating risk prediction performance for patients diagnosed with ductal carcinoma in situ.
• Analyzing cumulative incidence of invasive contralateral breast cancer, accounting for competing risks.

Strengths

• Large population-based cohort of 303,839 total patients from a nationwide cancer registry.
• Longitudinal data covering a 28-year period from 1989 to 2017.
• Includes detailed clinico-pathological and treatment data for multivariable modeling.

Limitations

• The primary dataset is not publicly available and requires a formal request process for access.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data reflects a single national registry (Netherlands), which may limit geographic generalizability.

Provenance

Source

Netherlands Cancer Registry (NCR), data request study number K18.245.

Collection Method

Patients were identified from the nationwide Netherlands Cancer Registry.

Time Range

1989-2017

Geography

Netherlands